ArticleFrontiers in pharmacology2025

The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis.

Wan Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.